AIMS: In patients with recently diagnosed non-ischaemic LV systolic dysfunction, left ventricular reverse remodelling (LVRR) and favourable prognosis has been documented in studies with short-term follow-up. The aim of our study was to assess the long-term clinical course and stability of LVRR in these patients. METHODS AND RESULTS: We prospectively studied 133 patients (37 women; 55 [interquartile range 46, 61] years) with recently diagnosed unexplained LV systolic dysfunction, with heart failure symptoms lasting <6 months and LV ejection fraction <40% persisting after at least 1 week of therapy. All patients underwent endomyocardial biopsy (EMB) at the time of diagnosis and serial echocardiographic and clinical follow-up over 5 years. LVRR was defined as the combined presence of (1) LVEF ≥ 50% or increase in LVEF ≥ 10% points and (2) decrease in LV end-diastolic diameter index (LVEDDi) ≥ 10% or (3) LVEDDi ≤ 33 mm/m2. LVRR was observed in 46% patients at 1 year, in 60% at 2 years and 50% at 5 years. Additionally, 2% of patients underwent heart transplantation and 12% experienced heart failure hospitalization. During 5-year follow-up, 23 (17%) of the study cohort died. In multivariate analysis, independent predictors of mortality were baseline right atrial size (OR 1.097, CI 1.007-1.196), logBNP level (OR 2.02, CI 1.14-3.56), and PR interval (OR 1.02, CI 1.006-1.035) (P < 0.05 for all). The number of macrophages on EMB was associated with overall survival in univariate analysis only. LVRR at 1 year of follow-up was associated with a lower rate of mortality and heart failure hospitalization (P = 0.025). In multivariate analysis, independent predictors of LVRR were left ventricular end-diastolic volume index (OR 0.97, CI 0.946-0.988), LVEF (OR 0.89, CI 0.83-0.96), and diastolic blood pressure (OR 1.04, CI 1.01-1.08) (P < 0.05 for all). CONCLUSIONS: LVRR occurs in over half of patients with recent onset unexplained LV systolic dysfunction during first 2 years of optimally guided heart failure therapy and then remains relatively stable during 5-year follow-up. Normalization of adverse LV remodelling corresponds to a low rate of mortality and heart failure hospitalizations during long-term follow-up.

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Division of Cardiology University of Washington Medical Center Seattle WA USA

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29:270‐276. doi:10.1093/eurheartj/ehm342 PubMed DOI

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of cardiomyopathies. Circulation 2006;113:1807‐1816. doi:10.1161/CIRCULATIONAHA.106.174287 PubMed DOI

Nijst P, Martens P, Mullens W. Heart failure with myocardial recovery ‐ The patient whose heart failure has improved: what next? Prog Cardiovasc Dis 2017;60:226‐236. doi:10.1016/j.pcad.2017.05.009 PubMed DOI

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468‐1476. doi:10.1016/j.jacc.2010.11.030 PubMed DOI

Zou CH, Zhang J, Zhang YH, Wei BQ, Wu XF, Zhou Q, et al. Frequency and predictors of normalization of left ventricular ejection fraction in recent‐onset nonischemic cardiomyopathy. Am J Cardiol 2014;113:1705‐1710. doi:10.1016/j.amjcard.2014.02.028 PubMed DOI

Gilotra NA, Bennett MK, Shpigel A, Ahmed HM, Rao S, Dunn JM, et al. Outcomes and predictors of recovery in acute‐onset cardiomyopathy: A single‐center experience of patients undergoing endomyocardial biopsy for new heart failure. Am Heart J 2016;179:116‐126. doi:10.1016/j.ahj.2016.06.019 PubMed DOI

Merlo M, Masè M, Vitrella G, Belgrano M, Faganello G, Di Giusto F, et al. Usefulness of addition of magnetic resonance imaging to echocardiographic imaging to predict left ventricular reverse remodeling in patients with nonischemic cardiomyopathy. Am J Cardiol 2018;122:490‐497. doi:10.1016/j.amjcard.2018.04.017 PubMed DOI

Ikeda Y, Inomata T, Iida Y, Iwamoto‐Ishida M, Nabeta T, Ishii S, et al. Time course of left ventricular reverse remodeling in response to pharmacotherapy: Clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. Heart Vessels 2016;31:545‐554. doi:10.1007/s00380-015-0648-2 PubMed DOI

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787‐1847. doi:10.1093/eurheartj/ehs104 PubMed DOI

Palecek T, Kuchynka P, Hulinska D, Schramlova J, Hrbackova H, Vitkova I, et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new‐onset unexplained dilated cardiomyopathy. Med Microbiol Immunol 2010;199:139‐143. doi:10.1007/s00430-009-0141-6 PubMed DOI

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107‐133. doi:10.1093/ejechocard/jep007 PubMed DOI

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440‐1463. doi:10.1016/j.echo.2005.10.005 PubMed DOI

Aretz HT. Myocarditis: The Dallas criteria. Hum Pathol 1987;18:619‐624. doi:10.1016/S0046-8177(87)80363-5 PubMed DOI

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2013;34:2636‐2648. doi:10.1093/eurheartj/eht210 PubMed DOI

Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007;28:2256‐2295. doi:10.1093/eurheartj/ehm305 PubMed DOI

Lawless JF, Singhal K. Efficient screening of nonnormal regression models. Biometrics 1978;34:318‐327. doi:10.2307/2530022 DOI

McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: Results of the IMAC (intervention in myocarditis and acute cardiomyopathy)‐2 study. J Am Coll Cardiol 2011;58:1112‐1118. doi:10.1016/j.jacc.2011.05.033 PubMed DOI PMC

Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553‐576. doi:10.1002/ejhf.1461 PubMed DOI

Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, et al. Effect of left ventricular reverse remodeling on long‐term prognosis after therapy with angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011;107:1065‐1070. doi:10.1016/j.amjcard.2010.11.033 PubMed DOI

Sallach JA, Tang WH, Borowski AG, Tong W, Porter T, Martin MG, et al. Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging 2009;2:527‐534. doi:10.1016/j.jcmg.2009.01.012 PubMed DOI

Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one‐year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147‐152. doi:10.1016/0002-9149(84)90320-5 PubMed DOI

Li X, Chen C, Gan F, Wang Y, Ding L, Hua W. Plasma NT pro‐BNP, hs‐CRP and big‐ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: A single‐center cohort study. BMC Cardiovasc Disord 2014;14:67. doi:10.1186/1471-2261-14-67 PubMed DOI PMC

Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators . Admission B‐type natriuretic peptide levels and in‐hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943‐1950. doi:10.1016/j.jacc.2007.02.037 PubMed DOI

Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction. Circulation 2005;111:887‐893. doi:10.1161/01.CIR.0000155616.07901.35 PubMed DOI

Kuethe F, Franz M, Jung C, Porrmann C, Reinbothe F, Schlattmann P, et al. Outcome predictors in dilated cardiomyopathy or myocarditis. Eur J Clin Invest 2017;47:513‐523. doi:10.1111/eci.12772 PubMed DOI

Kažukauskienė I, Baltrūnienė V, Jakubauskas A, Žurauskas E, Maneikienė VV, Daunoravičius D, et al. Prevalence and prognostic relevance of myocardial inflammation and cardiotropic viruses in non‐ischemic dilated cardiomyopathy. Cardiol J 2022;29:441‐453. doi:10.5603/CJ.a2020.0088 PubMed DOI PMC

Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118:639‐648. doi:10.1161/CIRCULATIONAHA.108.769489 PubMed DOI

Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, et al. Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 2021;23:854‐871. doi:10.1002/ejhf.2190 PubMed DOI

Akhtar MM, Lorenzini M, Cicerchia M, Ochoa JP, Hey TM, Sabater Molina M, et al. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN gene. Circ Heart Fail 2020;13:e006832. doi:10.1161/CIRCHEARTFAILURE.119.006832 PubMed DOI